Claims for Patent: 9,458,172

Summary for Patent: 9,458,172

Title:	Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives
Abstract:	Disclosed are certain pyridinyl and pyrimidinyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds and methods of treatment using such compounds.
Inventor(s):	Bair; Kenneth W (Watertown, MA), Baumeister; Timm R (Watertown, MA), Dragovich; Peter (South San Francisco, CA), Gosselin; Francis (South San Francisco, CA), Yuen; Po-Wai (Beijing BDA, CN), Zak; Mark (South San Francisco, CA), Zheng; Xiaozhang (Watertown, MA)
Assignee:
Application Number:	14/382,123
Patent Claims:	1. A compound of Formula (I): ##STR00229## wherein: A is CH or N; E is O or is absent; R is (a) a bicyclic heteroaryl comprising one or more heteroatom ring members independently selected from N, S or O, wherein said bicyclic heteroaryl is unsubstituted or is substituted with one or more substituents selected from the group consisting of deuterium, amino, alkylamino, dialkylamino, alkyl, halo, cyano, haloalkyl, hydroxy, hydroxyalkyl, and alkoxy; and wherein one or more N ring members of said bicyclic heteroaryl is optionally an N-oxide; or (b) a five- or six-membered nitrogen-linked heterocycloalkyl ring fused to a phenyl or monocyclic heteroaryl, wherein said phenyl or heteroaryl is unsubstituted or is substituted with one or more substituent selected from the group consisting of deuterium, amino, alkylamino, dialkylamino, alkyl, halo, cyano, haloalkyl, hydroxy, hydroxyalkyl, and alkoxy; R.sup.1 is (1) R.sup.m or -alkylenyl-R.sup.m, where R.sup.m is cycloalkyl, heterocycloalkyl, phenyl, or monocyclic heteroaryl; wherein each of said cycloalkyl, heterocycloalkyl, phenyl, and heteroaryl is unsubstituted or is substituted with one or more substituents R.sup.x; wherein each R.sup.x substituent is independently selected from the group consisting of: deuterium, halo, hydroxy, hydroxyalkyl, cyano, --NR.sup.aR.sup.b, -alkylenyl-NR.sup.aR.sup.b, oxo, alkyl, cyanoalkyl, haloalkyl, alkoxy, --S-alkyl, haloalkoxy, alkoxyalkyl-, alkenyl, alkynyl, --C(O)alkyl, --C(O)alkyl-O-alkyl, --CO.sub.2alkyl, --CO.sub.2H, --CONH.sub.2, --C(O)NH(alkyl), --C(O)NH(haloalkyl), --C(O)N(alkyl).sub.2, --C(O)NH(cycloalkyl), arylalkyl-, arylalkoxy-, aryloxy-, cycloalkyl, cycloalkyloxy, (cycloalkyl)alkyl, heterocycloalkyl, aryl, (heterocycloalkyl)alkyl-, (heterocycloalkyl)alkoxy-, --C(O)cycloalkyl, --C(O)heterocycloalkyl, heteroaryl, (heteroaryl)alkyl-, --S(O)-alkyl, --SO.sub.2 -alkyl, --SO.sub.2 -aryl, --SO.sub.2-fluoroalkyl, --N(R.sup.c)--C(O)-alkyl, --N(R.sup.c)--C(O)-aryl, --N(R.sup.c)--CO.sub.2-alkyl, --SO.sub.2NH.sub.2, --SO.sub.2NH(alkyl), --SO.sub.2N(alkyl).sub.2, --SO.sub.2NH(cycloalkyl), and --N(H)(SO.sub.2alkyl), or two adjacent R.sup.x substituents on a phenyl or heteroaryl R.sup.m groups taken together form methylenedioxy, wherein each of said cycloalkyl, heterocycloalkyl, aryl, and heteroaryl within R.sup.x is unsubstituted or is substituted with one or more substituents independently selected from the group consisting of deuterium, alkyl, halo, hydroxy, cyano, alkoxy, amino, --C(O)alkyl, and --CO.sub.2alkyl; wherein R.sup.a and R.sup.b are each independently H, alkyl, alkoxy, alkoxyalkyl, cyanoalkyl, or haloalkyl; and R.sup.c is H, alkyl or arylalkyl-; (2) alkyl unsubstituted or substituted with one or more substituents selected from the group consisting of deuterium, halo, hydroxy, cyano, alkoxy, haloalkoxy, --NR.sup.sR.sup.t, --C(O)alkyl, CO.sub.2alkyl, --CO.sub.2H, --CONR.sup.s R.sup.t, --SOalkyl, --SO.sub.2alkyl, and --SO.sub.2NR.sup.sR.sup.t; where R.sup.s and R.sup.t are each independently H, alkyl, alkoxyalkyl, haloalkyl, --C(O)alkyl, or --CO.sub.2alkyl; or (3) --N(R.sup.n)R.sup.o, wherein R.sup.n is H, R.sup.m, -alkylenyl-R.sup.m, hydroxyalkyl, cyanoalkyl, alkoxyalkyl, haloalkyl, --CONR.sup.hR.sup.i, or --C(O)R.sup.j; where R.sup.m is as defined in (1) above; R.sup.h and R.sup.i are each independently H or alkyl, or R.sup.h and R.sup.i taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl; and R.sup.j is an alkyl unsubstituted or substituted with one or more substituents selected from the group consisting of: deuterium, halo, amino, hydroxy, alkoxy, cycloalkyl, heteroaryl, phenyl, and heterocycloalkyl; or a cycloalkyl, heterocycloalkyl, phenyl, or heteroaryl, each unsubstituted or substituted with one or more substituents selected from the group consisting of: deuterium, alkyl, halo, amino, hydroxy, and alkoxy; and R.sup.o is H or R.sup.j; R.sup.2 and R.sup.3 are each independently selected from the group consisting of H and deuterium; wherein the compound of Formula I is not 1H-pyrrolo[3,2-c]pyridine-2-carboxylic acid (5-benzenesulfonyl-pyridin-2-ylmethyl)-amide; or a pharmaceutically acceptable salt thereof. 2. The compound of claim 1, wherein R is an unsubstituted or substituted 8- or 9-membered heteroaryl. 3. The compound of claim 1, wherein R is: ##STR00230## each unsubstituted or substituted as in claim 1. 4. The compound of claim 1, wherein R is a five- or six-membered nitrogen-linked heterocycloalkyl ring fused to an unsubstituted or substituted phenyl or monocyclic heteroaryl. 5. The compound of claim 1, wherein R is ##STR00231## 6. The compound of claim 1, wherein R.sup.1 is R.sup.m, wherein R.sup.1 is -alkylenyl-R.sup.m. 7. The compound of claim 1, wherein R.sup.m is cycloalkyl, unsubstituted or substituted as in claim 1. 8. The compound of claim 1, wherein R.sup.m is a heterocycloalkyl, unsubstituted or substituted with an alkyl, --C(O)alkyl, or monocyclic heterocycloalkyl group. 9. The compound of claim 1, wherein R.sup.m is phenyl, pyridinyl, pyrazolyl, pyrimidinyl, thiazolyl, or pyrazinyl, each unsubstituted or substituted as in claim 1. 10. The compound of claim 1, wherein the R.sup.m group is substituted with one or more R.sup.x substituents each independently selected from the group consisting of: fluoro, chloro, bromo, hydroxy, hydroxymethyl, hydroxyethyl, cyano, amino, di(alkyl)amino, alkylamino, monofluoroalkyl, trifluoroalkyl, methoxy, ethoxy, trifluoromethoxy, acetyl, propionyl, butyryl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, carboxyl, methylsulfonyl, ethylsulfonyl, trifluoromethylsulfonyl, methylamido, ethylamido, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, tetrahydropyranyl, morpholinyl, piperazinyl, pyridinyl, imidazolyl, pyrrolyl, pyrimidinyl, and phenyl, each substituted or unsubstituted as in claim 1. 11. The compound of claim 1, wherein the Rm group is substituted with 1, 2, or 3 R.sup.x substituents each independently selected from the group consisting of: fluoro, trifluoromethyl, trifluoromethoxy, morpholinyl, 4-methyl-piperazinyl, piperidinyl, methoxy, cyano, acetyl, ethylamido, methylsulfonyl, ethylsulfonyl, cyano, chloro, dimethylamino, methyl, ethyl, propyl, isopropyl, isobutyl, butyryl, oxetanyl, tetrahydropyranyl, pyrrolidinyl, and 1-(3-oxetanyl)-piperidin-4-yl. 12. The compound of claim 1, wherein R.sup.1 is an alkyl, unsubstituted or substituted with one or more substituents selected from the group consisting of halo, hydroxy, cyano, alkoxy, trifluoroalkyl, trifluoroalkoxy, amino, methylamino, dimethylamino, acetyl, methoxycarbonyl, amido, and methylsulfonyl. 13. The compound of claim 1, wherein R.sup.1 is --N(R.sup.n)R.sup.o, and R.sup.n is R.sup.m or -alkylenyl-R.sup.m. 14. The compound of claim 13, wherein R.sup.n is hydroxyalkyl, cyanoalkyl, alkoxyalkyl, haloalkyl, --CONR.sup.hR.sup.i, or --C(O)R.sup.j, where R.sup.h and R.sup.i are each independently H or alkyl, and R.sup.j is hydroxymethyl, cycloalkyl, piperidinyl, or phenyl. 15. The compound of claim 1, wherein both R.sup.2 and R.sup.3 are H. 16. A compound selected from the group consisting of: ##STR00232## ##STR00233## ##STR00234## ##STR00235## ##STR00236## ##STR00237## ##STR00238## ##STR00239## ##STR00240## ##STR00241## ##STR00242## ##STR00243## ##STR00244## ##STR00245## ##STR00246## ##STR00247## ##STR00248## ##STR00249## ##STR00250## ##STR00251## ##STR00252## ##STR00253## ##STR00254## ##STR00255## ##STR00256## ##STR00257## ##STR00258## ##STR00259## ##STR00260## ##STR00261## ##STR00262## ##STR00263## and pharmaceutically acceptable salts thereof, stereoisomers thereof, and pharmaceutically acceptable salts of stereoisomers thereof. 17. A pharmaceutical composition comprising: (a) an effective amount of at least one compound of claim 1; and (b) a pharmaceutically acceptable carrier. 18. The pharmaceutical composition of claim 17, further comprising therapeutically effective amounts of one or more additional adjunctive active agents, or a rescuing agent, wherein said one or more additional adjunctive active agents are selected from the group consisting of a cytotoxic agent, cisplatin, doxorubicin, taxotere, taxol, etoposide, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, the epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, temozolomide, cyclophosphamide, SCH 66336, tipifarnib, R115777, L778,123, BMS 214662, gefitinib, erlotinib, C225, imatinib, Interferon alfa-2b, PEGinterferon alfa-2b, aromatase combinations, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, leucovirin, oxaliplatin, Pentostatine, vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17a-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrol acetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, Hexamethylmelamine, Avastin, herceptin, Bexxar, Velcade, Zevalin, Trisenox, Xeloda, Vinorelbine, Porfimer, Erbitux, Liposomal, Thiotepa, Altretamine, Melphalan, Trastuzumab, Lerozole, Fulvestrant, Exemestane, Ifosfomide, Rituximab, C225, Campath, leucovorin, dexamethasone, bicalutamide, chlorambucil, letrozole, megestrol, valrubicin, vinblastine, and niacin extended-release, wherein the rescuing agent is selected from the group consisting of nicotinamide, nicotinic acid, and nicotinamide mononucleotide (NMN). 19. A method of treating a subject suffering from or diagnosed with a disease or medical condition mediated by nicotinamidephosphoribosyltransferase (NAMPT) activity, comprising administering to the subject in need of such treatment an effective amount of at least one compound of claim 1, wherein the disease or medical condition is a solid or liquid tumor, non-small cell lung cancer, leukemia, lymphoma, ovarian cancer, glioma, breast cancer, uterine cancer, colon cancer, cervical cancer, lung cancer, prostate cancer, skin cancer, rhino-gastric tumors, colorectal cancer, CNS cancer, bladder cancer, pancreatic cancer, Hodgkin's disease, rheumatoid arthritis, diabetes, atherosclerosis, sepsis, aging, inflammation. 20. The method of claim 19, further comprising administering to the subject an effective amount of a rescuing agent or at least one compound selected from the group consisting of: a cytotoxic agent, cisplatin, doxorubicin, taxotere, taxol, etoposide, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, the epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, temozolomide, cyclophosphamide, SCH 66336, tipifarnib, R115777, L778,123, BMS 214662, gefitinib, erlotinib, C225, imatinib, Interferon alfa-2b, PEGinterferon alfa-2b, aromatase combinations, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, leucovirin, oxaliplatin, Pentostatine, vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17a-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrol acetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, Hexamethylmelamine, Avastin, herceptin, Bexxar, Velcade, Zevalin, Trisenox, Xeloda, Vinorelbine, Porfimer, Erbitux, Liposomal, Thiotepa, Altretamine, Melphalan, Trastuzumab, Lerozole, Fulvestrant, Exemestane, Ifosfomide, Rituximab, C225, Campath, leucovorin, dexamethasone, bicalutamide, chlorambucil, letrozole, megestrol, valrubicin, vinblastine, and niacin extended-release, wherein the rescuing agent is selected from the group consisting of nicotinamide, nicotinic acid, and nicotinamide mononucleotide (NMN).

Details for Patent 9,458,172

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2032-03-02
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2032-03-02
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2032-03-02
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2032-03-02
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2032-03-02